ABK Biomedical Breaks Ground on New Missouri Facility for Cancer Treatment
ABK Biomedical kicks off construction of a new Missouri-based facility, partnering with local academic and construction leaders to accelerate the development of…
ABK Biomedical kicks off construction of a new Missouri-based facility, partnering with local academic and construction leaders to accelerate the development of…
New research from Amen Clinics highlights distinct neurological markers in postpartum depression, offering a clearer clinical distinction from major depressive disorder.
Encompass Health Corp. will report its Q3 2026 financial results on October 28, 2026, followed by an investor conference call scheduled for…
Sphere Health expands its clinical offerings with a new program focused on hormonal and metabolic health, addressing conditions ranging from PMOS to…
Bank of America pledges $10 million to Boston Children's Hospital to fund a new pediatric behavioral health campus in Brighton, focusing on…
Arrowfly expands its B2B media footprint with the launch of The Exchange Network, a new community platform tailored for healthcare executives to…
TIAA research highlights a growing retirement crisis, with 77% of Americans fearing healthcare costs will derail their long-term financial security as life…
miRoncol Health introduces miCheckup, a novel miRNA-based blood test designed to detect early-stage cancer signals, expanding the landscape of Canadian diagnostic screening…
ARMS Medical secures industry recognition as its VNEW mesh-free dermal allograft is named the Top Pelvic Floor Surgery Technology of 2026 by…
SpyGlass Pharma strengthens its supply chain by acquiring AVS from Santen Pharmaceutical for $13 million, securing essential manufacturing capacity for its Phase…
National Health Investors acquires six senior housing properties totaling 443 units for $107.7 million, expanding its footprint in Kentucky, Michigan, and Tennessee.
Lutris Pharma shares gain momentum after reporting that its LUT014 0.1% gel significantly outperformed placebo in Phase 2 trials, achieving a 71.8%…